Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like Molecule 2 (LOXL2), in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Next Previous
X
Search
Trial Profile

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like Molecule 2 (LOXL2), in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Simtuzumab (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
    • 08 Dec 2020 Results of an analysis (n=2154) assessing associations between histologic and non-invasive fibrosis tests with clinical and patient-reported outcomes from four clinical studies: NCT01672866, NCT01672879, NCT03053050 and NCT03053063 published in the Gastroenterology
    • 16 Apr 2019 Results from the Simtuzumab trials published in the Hepatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top